FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
Fortress Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.87+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $59.45M
- P/E (TTM)
- –
- Dividend yield
- –
Fortress Biotech, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | $18.51M | $15.96M | $16.08M | $17.63M | $15.01M | $13.14M | $13.62M | $14.63M | $14.86M | $13.03M | – | – | 98.9% | +23.3% |
| Fortress | $208.00K | $77.00K | – | – | – | – | – | – | – | – | – | – | 1.1% | – |
| Avenue | – | – | $0 | $0 | $1.40M | – | – | – | – | – | – | – | – | – |
| Checkpoint Merger | – | – | – | – | – | – | $0 | $0 | $41.00K | – | – | – | – | – |
| Pharmaceutical and Biotechnology Product Development | – | – | – | – | – | – | – | $0 | $41.00K | – | $4.69M | $213.00K | – | – |
| Dermatology Products Sales | – | – | – | – | – | – | – | $14.63M | $14.86M | $13.03M | $15.26M | $34.54M | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | $456.00K | -$1.49M | -$443.00K | -$1.53M | -$2.94M | -$3.32M | $2.23M | -$2.89M | -$2.93M | -$10.09M | – | – | -115.5% |
| Avenue | -$707.00K | -$714.00K | -$752.00K | -$724.00K | $297.00K | -$1.91M | -$1.60M | -$3.16M | -$2.82M | -$3.71M | – | – | -338.0% |
| Mustang | -$1.17M | -$1.06M | -$670.00K | -$624.00K | -$885.00K | -$253.00K | -$1.02M | -$1.46M | -$8.54M | -$5.23M | – | – | +32.2% |
| Fortress | -$8.59M | -$4.48M | -$2.92M | -$3.93M | -$6.06M | -$5.69M | $5.37M | -$4.86M | -$6.83M | -$6.59M | – | – | +41.6% |
| Checkpoint Merger | – | – | $0 | $0 | -$26.89M | -$11.15M | -$28.83M | -$9.72M | -$6.67M | -$10.95M | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emrosi | $8.07M | $6.25M | $5.00M | $4.88M | $2.80M | $2.07M | – | – | – | – | – | – | 43.1% | +188.9% |
| Qbrexza | $5.11M | $5.03M | $5.54M | $7.36M | $6.95M | $5.16M | $5.68M | $7.58M | $6.84M | $5.02M | $7.37M | $5.87M | 27.3% | -26.4% |
| Accutane | $3.36M | $3.31M | $3.06M | $2.77M | $3.40M | $3.66M | $3.87M | $4.00M | $5.72M | $5.82M | $5.06M | $4.88M | 17.9% | -1.1% |
| Foam franchise products (Amzeeq & Zilxi) | $941.00K | $1.05M | – | – | $1.14M | $1.53M | – | – | – | – | – | – | 5.0% | -17.1% |
| Other / legacy product revenue | $232.00K | $277.00K | $575.00K | $701.00K | $735.00K | $727.00K | $1.12M | $950.00K | $726.00K | $1.17M | $1.13M | $1.52M | 1.2% | -68.4% |
| Eurax | $120.00K | – | – | – | – | – | – | – | – | – | – | – | 0.6% | – |
| Targadox | – | – | – | – | – | – | – | – | – | – | $818.00K | $929.00K | – | – |
| Ximino | – | – | – | – | – | – | – | – | – | – | – | -$199.00K | – | – |
| Exelderm | – | – | – | – | – | – | – | – | – | – | $582.00K | $764.00K | – | – |
| Zilxi | – | – | – | – | $256.00K | $426.00K | $443.00K | $558.00K | $369.00K | $273.00K | $395.00K | $681.00K | – | – |
| Amzeeq | – | – | – | – | $879.00K | $1.10M | $1.51M | $1.54M | $1.21M | $755.00K | $1.30M | $2.34M | – | – |
| Collaboration revenue | – | – | – | – | – | – | – | – | – | – | $4.68M | $182.00K | – | – |
| Vyne acquisition products (Amzeeq & Zilxi) | – | – | – | $1.31M | – | – | – | $2.10M | – | – | – | – | – | – |
| Royalty revenue | – | $77.00K | $0 | $0 | – | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Fortress Biotech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.